Cellectar Biosciences Q1 2025 Net Loss Narrowed to $6.6M; Seeks EMA Conditional Approval for Iopofosine

Cellectar Biosciences, Inc.

2025-Q1 EPS reported -$0.14

Net loss for Q1 2025 was $6.6 million ($0.14 per share), compared to $26.6 million ($0.91 per share) in Q1 2024.
Company seeking conditional EMA approval for iopofosine I 131 in Waldenstrom macroglobulinemia based on CLOVER WaM Phase 2 data with 59% major response rate in BTKi-treated patients.
Cash and cash equivalents totaled $13.9 million as of March 31, 2025, expected to fund operations into Q4 2025.
Board engaged Oppenheimer & Co. as exclusive financial advisor to explore strategic alternatives including mergers, acquisitions, or partnerships.
Planned Phase 3 study for iopofosine I 131 would be a comparator randomized controlled study with 100 patients per arm, dependent on funding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.